2014
Virologic response and haematologic toxicity of boceprevir‐ and telaprevir‐containing regimens in actual clinical settings
Butt AA, Yan P, Shaikh OS, Freiberg MS, Re V, Justice AC, Sherman KE, Team T. Virologic response and haematologic toxicity of boceprevir‐ and telaprevir‐containing regimens in actual clinical settings. Journal Of Viral Hepatitis 2014, 22: 691-700. PMID: 25524834, PMCID: PMC5020421, DOI: 10.1111/jvh.12375.Peer-Reviewed Original ResearchConceptsSustained virologic responsePEG/RBVHaematologic toxicityActual clinical settingsSVR ratesVirologic responseClinical settingHaematologic adverse eventsHCV Infected VeteransInterferon/ribavirinHCV genotype 1HCV RNA valuesPivotal clinical trialsHepatitis C virusBaseline cirrhosisHIV coinfectionPrimary endpointTreatment-naïveAdverse eventsC virusClinical trialsGenotype 1Genotype 1aSevere toxicityBoceprevir
2011
A Comparison of Treatment Eligibility for Hepatitis C Virus in HCV-Monoinfected Versus HCV/HIV-Coinfected Persons in Electronically Retrieved Cohort of HCV-Infected Veterans
Butt AA, McGinnis K, Skanderson M, Justice AC. A Comparison of Treatment Eligibility for Hepatitis C Virus in HCV-Monoinfected Versus HCV/HIV-Coinfected Persons in Electronically Retrieved Cohort of HCV-Infected Veterans. AIDS Research And Human Retroviruses 2011, 27: 973-979. PMID: 21338329, PMCID: PMC3719436, DOI: 10.1089/aid.2011.0004.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseHepatitis C virusDecompensated liver diseaseHCV-HIVTreatment eligibilityC virusCohort of HCVVA National Patient Care DatabaseNational Patient Care DatabasePharmacy Benefits Management databaseHCV treatment eligibilityHCV-HIV coinfectionRecent alcohol abuseHCV/HIVCurrent treatment guidelinesProportion of patientsObstructive pulmonary diseaseCoronary artery diseasePatient Care DatabaseActual clinical settingsCoinfected PersonsAggressive managementCommon contraindicationsPharmacy recordsRenal failure